Slingshot members are tracking this event:
Following Phase I/II trial results, Immunomedics (IMMU) to file sacituzumab govitecan for accelerated approval in triple-negative breast cancer in mid-2017
Slingshot Insights Explained
Feb 08, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Sacituzumab Govitecan, Accelarated Approval, Triple-negative Breast Cancer, Phase 1/2